home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550008.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
3KB
|
43 lines
Document 0008
DOCN M9550008
TI Constitutive production of nonenveloped human immunodeficiency virus
type 1 particles by a mammalian cell line and effects of a protease
inhibitor on particle maturation.
DT 9505
AU Babe LM; Craik CS; Department of Pharmaceutical Chemistry, University of
California,; San Francisco 94143-0446.
SO Antimicrob Agents Chemother. 1994 Oct;38(10):2430-9. Unique Identifier :
AIDSLINE MED/95142590
AB A stable cell line encoding the sequences of all the human
immunodeficiency virus type 1 proteins, with the exception of the gp160
envelope glycoprotein, was derived from transfection of monkey COS-7
cells. This cell line, referred to as CH-1, produces active viral
protease that correctly processes its natural substrates and yields
capsid particles. These particles contain reverse transcriptase activity
and packaged viral RNA but are noninfectious. The level of expression of
viral proteins is not toxic to the cells, yet it is comparable to that
observed for chronically infected lymphocytes. These constitutively
synthesized viral proteins provide a consistent system for the analysis
of potential inhibitors of late viral functions. The lack of gp160
increases the biosafety of this assay system, while it allows the
measurement of the effects on the production and release of capsid
particles. A human immunodeficiency virus type 1 protease inhibitor was
used to confirm the viral polyprotein maturation pathway in this system.
Particles from cells treated with this protease inhibitor contain
unprocessed p55gag precursor and have the same density as the mature
particles. These immature particles contain viral RNA, but reverse
transcriptase activity is significantly reduced. This cell line may
serve to identify compounds that are able to affect viral assembly and
maturation as well as to identify the interactions between the viral and
cellular proteins involved in these essential processes.
DE Base Sequence Capsid/CHEMISTRY Cell Line HIV Core Protein
p24/ANALYSIS HIV Protease/GENETICS HIV Protease
Inhibitors/*PHARMACOLOGY HIV-1/DRUG EFFECTS/*PHYSIOLOGY/ULTRASTRUCTURE
Molecular Sequence Data Oligopeptides/*PHARMACOLOGY RNA,
Viral/METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.
Virus Replication JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).